This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Allscripts Names Catherine Burzik To Board Of Directors

CHICAGO, Oct. 27, 2011 /PRNewswire/ -- Allscripts (Nasdaq: MDRX) announced the appointment of Catherine Burzik, President and Chief Executive Officer of Kinetic Concepts, Inc. (KCI), to its Board of Directors. Burzik will add her unique experience to the Board and brings the number of directors to nine.

(Photo: http://photos.prnewswire.com/prnh/20111027/CG94535)

(Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO)

Ms. Burzik joined KCI in 2006 and has grown the company in revenue and profitability while doubling its market capitalization. KCI (NYSE: KCI) is a leading global medical technology company focused on advanced wound care, regenerative medicine, and therapeutic surfaces, all of which contribute to healing and improved outcomes for patients.  Under Ms. Burzik's leadership, KCI moved into the regenerative medicine business by acquiring biotech company LifeCell in 2008. KCI reported revenue of $2.0 billion for 2010 and employs nearly 7,000 people worldwide.

Before leading KCI, Ms. Burzik served as President and previously as Chief Operating Officer of Applied Biosystems Group, a global provider of hardware, software and reagents to life scientists. She served as the Chief Executive Officer and President of Kodak Health Imaging Systems Inc., a subsidiary of Eastman Kodak Company, as well as its General Manager, Vice President, Corporate Marketing.  She was also employed by Johnson & Johnson, where she served as the President of its Ortho-Clinical Diagnostics Inc. subsidiary from 1998 to 2003, and General Manager of its Critikon Inc. business from 1997 to 1998.

" Cathy Burzik has been a significant contributor to the growth and development of some of the world's best-known companies," said Glen Tullman, Chief Executive Officer of Allscripts. "Her years of leadership experience include a strong focus on operations and a unique ability to recognize the next chapter in healthcare technology, which will help Allscripts as we continue to broaden our business strategy."

Allscripts Chairman Phil Pead commented, "We are excited to welcome Cathy Burzik to our board. Her outstanding business track record, leadership and operational strengths will be of great value to our board and will help Allscripts stay at the forefront of client-driven innovation."

Ms. Burzik commented, "I'm delighted to serve on the Allscripts Board of Directors. I look forward to offering my perspective to help shape the strategic direction of Allscripts, a company that not only shares KCI's commitment to helping patients and providers through innovative new products, but connects them to each other and to the information and insights they need to deliver better outcomes."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs